Anti‐epilepsy drug therapy in a dox‐regulatable TDP‐43 mouse model of ALS‐FTD with seizures
Irene Ra, Elizabeth Jia, Jaskreet Gujral, William Rodemer, Sílvia Porta, Virginia M‐Y Lee · 2025
Read Anti‐epilepsy drug therapy in a dox‐regulatable TDP‐43 mouse model of ALS‐FTD with seizures by Irene Ra, Elizabeth Jia, Jaskreet Gujral, William Rodemer, Sílvia Porta, Virginia M‐Y Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713330.txt.
Description
Irene Ra and co-authors test a seizure drug in a mouse model of ALS and frontotemporal dementia, in this 2025 paper. A protein called TDP-43 builds up in most cases of both diseases. The build-up may make brain cells too excitable, which can harm them and trigger seizures.
The mice were bred so the protein shift could be switched on. Sixteen mice got daily doses of the seizure drug levetiracetam or a plain control. After four weeks they faced tests of thinking, social behavior, and movement. The authors check whether calming cell activity protects the brain, which would point to a treatment path for patients with seizures.
Catalog record
| CREATOR | Irene Ra, Elizabeth Jia, Jaskreet Gujral, William Rodemer, Sílvia Porta, Virginia M‐Y Lee |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |